Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...

President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Mounjaro. Ozempic. Wegovy. Zepbound. All these are brand names linked in some way to diabetes and weight loss-or, as the ...

Novo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna ...

Shares of Septerna Inc. were soaring in Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.